Zynex Inc

Zynex — Investor Presentation (December 2013)

26 slides from Zynex's investor presentation, Dec 31, 2013

  1. Slide 1: Zynex

    ZYNIEXD

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumstances, inform

  3. Slide 3: Zynex Overview

    Zynex Overview Medical Device Manufacturer & Compound Pharmacy Non-invasive, conservative pain treatment EEG & Sleep diagnostics Blood volume monitoring Physician and hospital billing International sales Publicly Traded OTCQB: ZYXI In operation since 1996, headquartered in Lone Tree, Colorado >40%+

  4. Slide 4: Business Structure

    Business Structure Business Structure 12/19/2013 4 OTCQB: ZYXI

  5. Slide 5: Business Unit Summary

    Business Unit Summary ZYNEX MEDICAL (ZMI) Non-invasive electrotherapy pain management devices "TENS" (98% of historical revenue) RX required, insurance billed >70% GP, >40% recurring revenue (consumable supplies) Topical/transdermal pain cream (introduced Dec 2013) RX required, insurance billed, com

  6. Slide 6: Products - Zynex Medical

    Products - Zynex Medical Complete line of electrotherapy pain management devices-FDA cleared and CE marked Augments healing, alleviates swelling through increased blood circulation, and reduces both acute/chronic pain through the use of electrical currents Consumables required Require a prescription

  7. Slide 7: Products - Zynex Medical (Stroke/spinal cord rehabilitation)

    Products - Zynex Medical Stroke/spinal cord rehabilitation devices-FDA cleared and CE marked Augment healing, as well as assist in recovery for stroke, Spinal Cord Injuries and Traumatic Brain Injury, retrains muscles, increases range of motion Consumables required 12/19/2013 7 NeuroMove Consumables

  8. Slide 8: Products - Zynex Neurodiagnostics

    Products - Zynex Neurodiagnostics EEG/Sleep diagnostic devices used in Neuro clinics, sleep diagnosis labs and for home sleep diagnosis B:B sale Not dependent on insurance reimbursement 12/19/2013 8 BWIII - (in lab) Sleep Diagnostic product Sleep Profiler- (home) Sleep Diagnostic product OTCQB: ZYXI

  9. Slide 9: Products - Monitoring Solutions

    Products - Monitoring Solutions In development - non invasive blood volume monitor Used in operating and recovery rooms to detect blood loss and internal bleeding Clinical trials commenced Patent filed 12/19/2013 9 Blood Volume Monitor (in development) OTCQB: ZYXI

  10. Slide 10: Revenue Growth

    Revenue Growth 12/19/2013 10 OTCQB: ZYXI

  11. Slide 11: Financial Summary

    Financial Summary 12/19/2013 11 OTCQB: ZYXI

  12. Slide 12: Balance Sheet

    Balance Sheet Balance Sheet 12/19/2013 12 OTCQB: ZYXI

  13. Slide 13: Available Market

    Available Market 12/19/2013 13 OTCQB: ZYXI PAST AVAILABLE MARKET ~$4B PAST AVAILABLE MARKET ~$4B CURRENT AVAILABLE MARKET ~$7B CURRENT AVAILABLE MARKET ~$7B ZYNEX MEDICAL ZYNEX MEDICAL Electrotherapy Devices $550M Electrotherapy Devices $275M Compound Pain Cream $1.8B ZYNEX MONITORING SOLUTIONS ZYNE

  14. Slide 14: What Happened to Business

    What Happened to Business Electrotherapy Industry (Zynex Medical - TENS) Healthcare Reform CMS Decision TENS devices Lower Back Pain indication no longer covered by Medicare Affordable Care Act Commercial insurance following CMS Physicians confused by general "reform" change and required to generate

  15. Slide 15: Zynex Path to Recovery

    Zynex Path to Recovery Zynex Improve current TENS business as quickly as possible Expense reductions to current demand (headcount/other ancillary) Renegotiated current building lease Focus on workers compensation electrotherapy (TENS) orders (highest collection rate) Diversification Pain Cream Creat

  16. Slide 16: Zynex Path to Recovery (Monitoring and Billing)

    Zynex Path to Recovery Zynex Monitoring Solutions Untapped market need blood volume monitoring (safer surgery/recovery) Non-invasive B:B Product development Zynex Billing and Consulting Service based revenue Leverage insurance billing core competency 12/19/2013 16 OTCQB: ZYXI

  17. Slide 17: Zynex - Looking Forward

    Zynex - Looking Forward Zynex Medical (ZMI) Pain Cream/Compound Pharmacy facts Complements Zynex TENS non-invasive pain management product and is sold through same TENS channel and customer Highly fragmented with low concentration Approximately 80%+ GM Zynex NeuroDiagnostics(ZND) EEG/Sleep Diagnosti

  18. Slide 18: Zynex - Looking Forward (Monitoring and Billing)

    Zynex - Looking Forward Zynex Monitoring Solutions: Blood Volume Monitor at commercialization Early warning that patient condition is likely to deteriorate Utilizes multiple physiological Enables a higher level of care than traditional vital sign monitoring Effective in multiple care environments (e

  19. Slide 19: Future Objectives

    Future Objectives Listing on AMEX/NASDAQ Develop devices and applications with high GPM Continue to grow recurring revenue Take only calculated risks Continue net earnings growth plan Positive free cash flow Utilize a mix of acquisitions and organic based growth to drive valuation=stock price=privat

  20. Slide 20: History

    History History 12/19/2013 20 OTCQB: ZYXI

  21. Slide 21: Corporate & Ownership Structure

    Corporate & Ownership Structure 12/19/2013 21 Common Stock: 31,000,000 shares outstanding OTCBB: ZYXI Auditors: GHP Horwath Counsel: Perkins Coie OTCQB: ZYXI

  22. Slide 22: Management Team Bio

    Management Team Bio Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been

  23. Slide 23: Management Team Bio

    Management Team Bio Robert "Bob" Cozart is the VP of Technical Operations who develops and manages all of the teams that make up the Purchasing, Production, Service, Warehouse, Facilities, and Shipping and Receiving departments. Mr. Cozart has over 26 years of management experience in electronics ma

  24. Slide 24: Summary

    Summary Summary 12/19/2013 24 High GPM of >70% >40%+ recurring revenue >40,000 units in the field >200,000 patients helped since inception Estimated $7b market OTCQB: ZYXI

  25. Slide 25: Contact Information

    Contact Information For more information, please contact: Investor Relations Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com 12/19/2013 25 OTCQB: ZYXI

  26. Slide 26: Stock Symbol ZYXI

    Stock Symbol ZYXI 12/19/2013 26 OTCQB: ZYXI

Zynex — Investor Presentation (December 2013) on 6ix